EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Association of Albuminuria Within the Normoalbuminuric Range With All‐Cause Mortality in People With Type 2 Diabetes

Monia Garofolo iD, Giuseppe Penno iD, Anna Solini iD, Emanuela Orsi iD, Martina Vitale iD, Veronica Resi, Enzo Bonora iD, Cecilia Fondelli, Roberto Trevisan iD, Monica Vedovato, Antonio Nicolucci iD, Giuseppe Pugliese iD und 1 weitere

Diabetes/Metabolism Research and Reviews · 2025

DOI: 10.1002/dmrr.70061 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2025. Verfasst von Monia Garofolo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Albuminuria, Renal Insufficiency, Chronic, Diabetic Nephropathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Diabete Ricerca, Fondazione Diabete Endocrinologia Metabolismo, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate the independent association of albuminuria within the normoalbuminuric range with all‐cause mortality in normoalbuminuric people with type 2 diabetes with and without chronic kidney disease (CKD). Materials and Methods This observational, prospective, multicentre, cohort study enroled 15,773 individuals with type 2 diabetes in 2006–2008. At baseline, albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR) were assessed together with cardiometabolic risk profile, treatments, complications, and comorbidities. All‐cause mortality was verified on 31 October 2015.

Results

Of the 15,656 participants (99.3%) with valid information on vital status, 11,460 (71.2%) were normoalbuminuric, 9984 (87.1%) without and 1476 (12.9%) with CKD. Normoalbuminuric individuals were stratified into three (< 5, 5–15, and > 15 mg·day −1 ) or two (< 10 and 10–29 mg·day −1 ) AER subcategories. When adjusting for age, sex, eGFR, prior cardiovascular disease, cardiovascular risk factors, and treatments, mortality risk was higher in participants with AER 10–29 versus < 10 mg·day −1 (hazard ratio, 1.120 [95% confidence interval, 1.028–1.221], p = 0.009) and 15–29 versus < 5 mg·day −1 (1.243 [1.099–1.406], p < 0.0001). When stratifying by CKD status, the adjusted risk remained significantly increased only for AER 15–29 versus < 5 mg/24 h in individuals with (1.404 [1.111–1.774], p = 0.005) and, to a lesser extent, without (1.167 [1.009–1.350], p = 0.038) CKD. A non‐linear association was observed between AER as Log2 transformed continuous variable and mortality.

Conclusions

For the same level of kidney function, higher AER within the normoalbuminuric range was independently associated with all‐cause mortality, thus supporting to the use of albuminuria‐lowering drugs in people with type 2 diabetes and mildly elevated albuminuria. Trial Registration ClinicalTrials.gov, NCT00715481, retrospectively registered 15 July, 2008.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2AlbuminuriaRenal Insufficiency, ChronicDiabetic NephropathiesBiomarkersHumansMaleFemaleProspective StudiesMiddle AgedGlomerular Filtration RateAgedFollow-Up StudiesPrognosisRisk FactorsCause of DeathSurvival Rate

Stichwörter der Autor:innen

albuminuriaall‐cause mortalitychronic kidney diseaseestimated glomerular filtration ratetype 2 diabetes

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
  • Diabetes Unit, Fondazione IRCCS "Cà Granda - Ospedale Maggiore Policlinico", Milan, Italy.
  • Department of Clinical and Molecular Medicine, "La Sapienza" University, Rome, Italy.
  • Division of Endocrinology, Diabetes and Metabolism, University and Hospital Trust of Verona, Verona, Italy.
  • Diabetes Unit, University of Siena, Siena, Italy.

ORCID-Profile: Monia Garofolo, Giuseppe Penno, Anna Solini, Emanuela Orsi, Martina Vitale, Enzo Bonora, Roberto Trevisan, Antonio Nicolucci, Giuseppe Pugliese

Förderung

  • Fondazione Diabete Ricerca
  • Fondazione Diabete Endocrinologia Metabolismo
  • Eli Lilly and Company
  • Sigma-Tau Pharmaceuticals
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Takeda Pharmaceutical Company

Zitieren

APA

Garofolo, M., Penno, G., Solini, A., Orsi, E., Vitale, M., Resi, V., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., Nicolucci, A., Pugliese, G., & Renal Insufficiency And Cariovascular Events (RIACE) Study Group (2025). Association of Albuminuria Within the Normoalbuminuric Range With All‐Cause Mortality in People With Type 2 Diabetes. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70061

Vancouver

Garofolo M, Penno G, Solini A, Orsi E, Vitale M, Resi V, et al. Association of Albuminuria Within the Normoalbuminuric Range With All‐Cause Mortality in People With Type 2 Diabetes. Diabetes/Metabolism Research and Reviews. 2025. doi:10.1002/dmrr.70061

BibTeX
@article{Garofolo2025,
  author = {Garofolo, Monia and Penno, Giuseppe and Solini, Anna and Orsi, Emanuela and Vitale, Martina and Resi, Veronica and Bonora, Enzo and Fondelli, Cecilia and Trevisan, Roberto and Vedovato, Monica and Nicolucci, Antonio and Pugliese, Giuseppe and Renal Insufficiency And Cariovascular Events (RIACE) Study Group, Renal Insufficiency And Cariovascular Events (RIACE) Study Group},
  title = {Association of Albuminuria Within the Normoalbuminuric Range With All‐Cause Mortality in People With Type 2 Diabetes},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2025},
  doi = {10.1002/dmrr.70061}
}
Kostenlos starten →